Treatment of recurrent squamous cell carcinoma of the head and neck with low doses of lnterleukin‐2 injected periiymphatically

Cancer

Volumn 62, Issue 12, 1988, Pages 2482-2485

  Cortesina, Giorgio ^a   de Stefani, Antonella ^a   Giovarelli, Mirella ^a   Barioglio, Maria Grazia ^a   Cavallo, Giovanni P ^a   Jemma, Cristina ^a   Forni, Guido ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2;

CLINICAL ARTICLE; HEAD AND NECK CANCER; HUMAN; INFLAMMATION; INTRALYMPHATIC DRUG ADMINISTRATION; LYMPH NODE; PAIN; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; FEMALE; HEAD AND NECK NEOPLASMS; HUMAN; INJECTIONS, INTRALYMPHATIC; INTERLEUKIN-2; LYMPHATIC METASTASIS; MALE; MIDDLE AGE; NEOPLASM RECURRENCE, LOCAL; SUPPORT, NON-U.S. GOV'T;

EID: 0024206262     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/1097-0142(19881215)62:12<2482::AID-CNCR2820621205>3.0.CO;2-9     Document Type: Article

References (26)

1. MHC molecules as guides for T lymphocytes parallel sets
2. Immune recognition of tumor cells in vivo: I. Role of H‐2 gene products in T‐lymphocyte activation against minor histocompatibility antigens displayed by adenocarcinoma cells
3. Quantitative variation in la antigen expression plays a central role in immune regulation
4. Immunization with antigen and interleukin 2 in vivo overcomes Ir gene low responsiveness
5. In vivo activity of interleukin‐2: Conversion of a stimulus causing unresponsiveness to a stimulus causing contact hypersensitivity by the injection of interleukin‐2
6. In vivo and in vitro administration of interleukin‐2 containing preparations reverses T‐cell unresponsiveness in Mycobacterium bovis BCG‐infected mice
7. A diet enriched in vitamin A acetate or in vivo administration of interleukin‐2 can counteract a tolerogenic stimulus
8. Lymphokine activated tumor inhibition in vivo: I. The local administration of Interleukin‐2 triggers nonreactive lymphocytes from tumor bearing mice to inhibit tumor growth
9. Interleukin‐2 activated tumor inhibition in vivo depends on the systemic involvement of host immunoreactivity
10. Tumor inhibition by interleukin‐2 at the tumor/host interface
11. Lymphokine activated tumor inhibition (LATI) in vivo
12. Delayed hypersensitivity reactions in patients with cancer
13. Delayed hypersensitivity reactions in patients with squamous cell cancer of the head and neck
14. Evaluation of blocking mechanisms against immunological response in patients with laryngeal carcinoma
15. Production of leukocyte migration inhibition factor by lymphocytes of larynx cancer patients stimulated by laryngeal carcinoma solubilized membrane antigens
16. Recommendations from the Declaration of Helsinki
17. In vivo administration of purified human interleukin‐2: I. Half life and immunological effects of Jurkat cell‐line derived interleukin‐2
18. T cell growth factor: Parameters of production and quantitative microassay for activity
19. A microcomputer program analysis of interleukin‐2 (IL‐2) titration data
20. Cervical lymphography: Difficulties and advantages
21. A progress report on the treatment of 157 patients with advanced cancer using lymphokine‐activated killer cells and interleukin‐2 or high‐dose interleukin‐2 alone
22. Constant‐infusion re‐combinant interleukin‐2 in adoptive immunotherapy of advanced cancer
23. The use of nitrogen mustard in the palliative treatment of carcinoma
24. Use of stomach as an esophageal substitute